<DOC>
	<DOCNO>NCT02793817</DOCNO>
	<brief_summary>The primary objective study investigate efficacy safety KPI-121 1.0 % ophthalmic suspension compare placebo subject undergone cataract surgery .</brief_summary>
	<brief_title>Safety Efficacy KPI-121 Subjects With Postsurgical Inflammation Pain</brief_title>
	<detailed_description>This Phase III , multicenter , double-masked , randomize , placebo-controlled , parallel-group study design evaluate efficacy safety KPI-121 1.0 % ophthalmic suspension versus placebo subject require treatment postoperative anterior ocular inflammation .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>Candidates routine , uncomplicated cataract surgery In Investigator 's opinion , potential postoperative Snellen Distance VA pinhole method least 20/200 study eye . Known hypersensitivity/contraindication study product ( ) component . History glaucoma , intraocular pressure ( IOP ) &gt; 21 mmHg screen randomization visit , treat glaucoma either eye . Diagnosis : ongoing ocular infection ; severe/serious ocular condition judgment Investigator could confound study assessment limit compliance ; severe/serious systemic disease uncontrolled medical condition judgment Investigator could confound study assessment limit compliance ; expose investigational drug within 30 day prior screen 18 day follow surgery . In opinion Investigator study coordinator , unwilling unable comply study protocol unable successfully instill eye drop .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>postsurgical</keyword>
	<keyword>postoperative</keyword>
	<keyword>ocular</keyword>
	<keyword>cataract</keyword>
	<keyword>inflammation</keyword>
	<keyword>pain</keyword>
	<keyword>corticosteroid</keyword>
</DOC>